FDA extends review of Roche's Tecentriq by three months

Roche said on Thursday the U.S. Food and Drug Administration (FDA) had extended by three months the review period for Tecentriq in combination therapy as a first-line treatment for a form of lung cancer.


from Reuters: Health News https://ift.tt/2M3BslI

No comments:

Post a Comment

Teen struggling w/ weight + no support at home, where the hell do I even start?

So I’m a teenager and I’ve been overweight/obese basically my whole life. And it’s been messing with me pretty bad. For the record, I don’...